Intravitreal Injectable Market Size, Share, Growth, and Industry Analysis, By Type (Anti-VEGF, Steroids and Others), By Application (Macular Degeneration, Macular Edema, Uveitis, Retinal Vein Occlusion and Others), Regional Insights, and Forecast To 2032

• 

   Request a Free Sample To Get More Information on this Market

INTRAVITREAL INJECTABLE MARKET REPORT OVERVIEW

The global intravitreal injectable market size was USD 16.85 billion in 2023 and the market is projected to touch USD 30.94 billion by 2032 at a CAGR of 7.1% during the forecast period.

The intravitreal injectable market growth is owing to the increasing prevalence of eye diseases, advancements in drug delivery, and the convenience and accessibility of intravitreal injections. Intravitreal injections are a highly effective treatment for a variety of eye diseases, have a relatively low risk of side effects, and are relatively convenient for patients. The cost of intravitreal injections has decreased in recent years, making them more affordable for patients.

COVID-19 IMPACT

"Imposed Restrictions in the Economy which led to a decline in demand forthe Market"

The COVID-19 pandemic has been unprecedented and staggering, with experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels except this market. Intravitreal injections are a common treatment for a variety of eye diseases, including diabetic retinopathy, age-related macular degeneration (AMD), and retinal vein occlusions. These injections are typically administered in an outpatient setting, but the COVID-19 pandemic led to a decrease in outpatient visits and elective procedures.

The COVID-19 pandemic had a significant impact on the intravitreal injectable market. Intravitreal injections are a common treatment for a variety of eye diseases, including diabetic retinopathy, age-related macular degeneration (AMD), and retinal vein occlusion. These injections are typically given in an ophthalmologist's office, and require the patient to be in close contact with the healthcare provider. The impact of the pandemic on the intravitreal injectable market was not uniform. Some patients were able to continue receiving their injections without interruption, while others had to delay or cancel their appointments. Patients with high-risk medical conditions, such as diabetes and heart disease, were more likely to delay or cancel their appointments.

The pandemic also had an impact on the development of new intravitreal injectable drugs. Several clinical trials for new drugs were delayed or suspended due to the pandemic. However, the development of new drugs has continued, and several new intravitreal injectable drugs are expected to be approved in the coming years. The impact of the COVID-19 pandemic on the intravitreal injectable market is expected to be temporary. As the pandemic subsides, the number of intravitreal injections is expected to rebound. However, the pandemic has highlighted the need for new delivery methods for intravitreal drugs that do not require in-person visits to the doctor's office.

LATEST TRENDS

"Higher Standards of Performance by Increase in Infrastructure Spending to Grow Market Potentially"

The intravitreal injectable market is evolving rapidly, with new drugs, delivery methods, and business models emerging. Some of the latest trends include the development of new drugs targeting a variety of eye diseases, improvements in delivery methods to make injections more convenient and less invasive, the increased use of biosimilars, the rise of telemedicine, and the growing demand in emerging markets.

INTRAVITREAL INJECTABLE MARKET SEGMENTATION

By Type

Based on type the intravitreal injectable market share is classified as Anti-VEGF, Steroids and Others.

By Application

Based on application the intravitreal injectable market share is classified as Macular Degeneration, Macular Edema, Uveitis, Retinal Vein Occlusion and Others.

DRIVING FACTORS

"Increasing prevalence of eye diseases which leads to the market growth"

The global prevalence of eye diseases is increasing, due to aging populations, rising levels of obesity and diabetes, and environmental factors such as pollution. This is leading to an increased demand for treatments for eye diseases, such as intravitreal injections.

"Growing demand in emerging markets for market growth"

The intravitreal injectable market is growing rapidly in emerging markets, such as China and India. This is due to the increasing prevalence of eye diseases in these countries, as well as the growing middle class, which can afford the high cost of intravitreal injections.

RESTRAINING FACTORS

"Several Challenges Associated with the Local Irritation to Restrain the Market Growth"

The intravitreal injectable market is facing a number of restraining factors, including the high cost of the injections, the risk of side effects, the need for repeated injections, competition from other treatment options, and regulatory hurdles. These factors are likely to slow the growth of the market in the coming years.

The high cost of intravitreal injections is a major barrier for patients who do not have insurance or who cannot afford the high cost of the injections. The risk of side effects, such as eye pain, redness, and blurred vision, can also be a concern for patients. Intravitreal injections are typically required every few months, which can be inconvenient for patients and can also be expensive. There are other treatment options available for some eye diseases, such as laser surgery and photodynamic therapy. These treatment options may be less expensive or have fewer side effects than intravitreal injections. The development and approval of intravitreal injectable drugs is a complex and lengthy process, which can delay the introduction of new drugs to the market and can make it difficult for companies to compete in the market.

• 

   Request a Free Sample To Get Analysis on Major Geographic Market

INTRAVITREAL INJECTABLE MARKET REGIONAL INSIGHTS

"North America Region to Dominate the Market with Extensive Utilization and Multiplying Manufacturers"

North America is the largest market for intravitreal injectables, accounting for a share of over 40% in 2022. This is due to the high prevalence of eye diseases in the region, as well as the availability of reimbursement for intravitreal injections. The United States is the largest market in North America, followed by Canada and Mexico.

KEY INDUSTRY PLAYERS

"Financial Players to Contribute Towards Expansion of Market"

The intravitreal injectable market is highly competitive, with a number of companies developing new drugs and delivery methods. The market is expected to continue to grow in the coming years, driven by the increasing prevalence of eye diseases and the development of new and improved treatments. Some of the key industry players in the intravitreal injectable market include Regeneron Pharmaceuticals, Novartis, Alcon, Bausch + Lomb, F. Hoffmann-La Roche, Allergan, EyePoint Pharmaceuticals, and Kanghong Pharmaceutical. These companies are developing a variety of intravitreal injectable drugs for the treatment of a range of eye diseases, including age-related macular degeneration, diabetic macular edema, and cytomegalovirus retinitis.

List of Top Intravitreal Injectable Companies

• Regeneron Pharmaceuticals (Eylea) (U.S.)
• Allergan (Europe)
• EyePoint Pharmaceuticals (U.S.)
• Genentech (U.S.)
• Kanghong Pharmaceutical (Asia Pacific)

REPORT COVERAGE

The SWOT analysis and information on future developments are covered in the study. The research report includes a study of a number of factors that promote market growth. This section also covers the range of numerous market categories and applications that could potentially affect the market in the future. The specifics are based on current trends and historical turning points. The state of the market's components and its potential growth areas over the following years. The paper discusses market segmentation information, including subjective and quantitative research, as well as the impact of financial and strategy opinions. Additionally, the research disseminates data on national and regional assessments that take into account the dominant forces of supply and demand that are influencing market growth. The competitive environment, including market shares of significant competitors, is detailed in the report along with fresh research methodology and player strategies for the anticipated time.